The latest announcement is out from Fusion Pharmaceuticals (FUSN).
Fusion Pharmaceuticals Inc. has entered into a definitive arrangement with AstraZeneca AB and its subsidiary, where the latter will acquire all outstanding common shares of Fusion. Shareholders will receive $21.00 per share in cash and a contingent value right (CVR), which could mean an additional $3.00 per share if certain milestones are met. The deal is conditioned on shareholder and regulatory approvals, and if successful, it will reshape Fusion’s future in the pharmaceutical industry, with a focus on treatments for metastatic castration-resistant prostate cancer.
For an in-depth examination of FUSN stock, go to TipRanks’ Stock Analysis page.
